Answers are grounded in this paper and cite their sources.
A review of the literature indicated denosumab is gaining favorability in the oncology community, particularly with increasing frequency in GCTB. Will denosumab be the breakthrough GCTB treatment? Here, we provide a pertinent case example, a review of the literature regarding the history and basic science behind the use of denosumab for GCTB, highlight the newest insights into the dosing and duration of treatment, and note advancements in the field.
No takes yet. Share an insight, caveat, or question.
Miles et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: